Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Sivagini Prakash et al.|JAMA Neurology|2023Cited by 62
Patterns and predictors of multiple sclerosis phenotype transitionLuigi Pontieri, Melinda Magyari, Finn Sellebjerg et al.|Brain Communications|2024Cited by 8
Pediatric Onset Multiple Sclerosis (POMS): Exploring phenotypic characterization and pubertal influences in modulating the disease activity from the Danish MS Registry (DMSR)Silvy Pilotto, Melinda Magyari, Maura Pugliatti et al.|Multiple Sclerosis Journal|2025Cited by 3
Socioeconomic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based studyViktoria Papp, Melinda Magyari, Finn Sellebjerg et al.|Journal of Neurology Neurosurgery & Psychiatry|2024Cited by 2